Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia

Summary

A randomized, multi-centre trial was conducted between 2013-2016, including 128 patients with untreated CLL from eight hematological clinics in Sweden. Vaccination with polysaccharide pneumococcal vaccine (PPSV23) or conjugated pneumococcal vaccine (PCV13) was performed and the results were published 2018. PCV13 showed a superior immune response, measured as OPA (opsonophagocytic assays) and ELISA (enzyme-linked immunosorbent assay), compared to PPSV23. Immune cells analyses after primary immunization will be performed. Between 2019-2021 a prospective follow up study was conducted of the same cohort and also included a control group. The study participants have been revaccinated with pneumococcal vaccines with the aim to evaluate the effect of repeated dose of PCV13. The antibody response (measured as titer with FMIA (fluorescent multiplexed bead-based immunoassay) and antibody function with MOPA (multiplexed opsonophagocytic assay) will be performed. Studies investigating the dynamics of immune cells before and after primary immunization and revaccination will be performed. The study will give important answers about the optimal vaccination strategy in patients with CLL and can improve the vaccination recommendations in immunocompromised patients.

Timeline

Start

2019-01-01

Primary completion

2021-06-30

Completion

2022-10-01

Publications

• Kattstrom M, Uggla B, Virta C, Melin M, Ekstrom N, Magnuson A, Andersson PO, Hammarlund Y, Lockmer S, Nilsson I, Roth D, Svensson M, Tolf T, Kimby E, Noren T, Athlin S. Revaccination with pneumococcal conjugate vaccine five years after primary immunization improves immunity in patients with chronic lymphocytic leukemia. Haematologica. 2025 Aug 1;110(8):1774-1785. doi: 10.3324/haematol.2024.286942. Epub 2025 Mar 6.

Drugs

Indications